Compact Liquid Chromatography for Routine Screening in Drug Treatment Centers

项目摘要 药物滥用和精神卫生服务管理局（SAMHSA）制定了非法药物的指导方针， 监测筛查和确认试验。床旁（POC）筛查测定通常依赖于 免疫测定在给定药物类别的化合物之间缺乏特异性。确认测试通常 采用色谱-质谱联用（MS），这是一种强大的技术，能够 在复杂样品中鉴定相关的感兴趣分析物;然而，这种方法需要大量的， 昂贵的设备，需要技术专长来操作，因此将其排除在POC环境之外。在 在这个快速跟踪SBIR项目中，Axelon公司的科学家与色谱和药物合作， 学术界的分析专家和执业卫生保健专业人员的建议将进一步研究 开发一种紧凑的毛细管液相色谱（LC）平台，用于快速POC筛选药物， 虐待在第一阶段，将优化使用新型固相萃取（SPE）装置的样品制备， 自动化，将创建更长路径长度的UV吸收检测器流动池，并且毛细管LC固定 将研究和选择流动相和移动的相，以达到SAMHSA检测浓度临界值 使用紧凑型LC系统测定相关化合物的限度。在第二阶段，新型柱-柱和柱- 检测器组合、二极管阵列检测模块和数据处理方法 将开发色谱保留时间和紫外吸收比，以加强对这些物质的分析。 化合物，并提供及时的信息，以支持紧急患者治疗决策。这方面的主要方面 对于推进使用毛细管LC的POC化学分析领域是独特的建议是（1）改进 使用新型简单的离线和在线提取和浓缩装置的灵敏度，以及更长的路径长度 紫外吸收流动池;（2）色谱柱、溶剂和操作模式的组合，以实现最大LC 分离，以及（3）使用创新的串联柱-UV-检测器增强检测的选择性 组合，（4）一个新的紧凑型DAD紫外吸收检测器的毛细管LC，和（5）独特的数据处理 峰值去卷积的软件算法。这些创新对于POC分析领域来说是新的， 毛细管LC的广泛领域。从这个项目的结果将是一个关键的一步释放 POC药物筛查解决方案，与当前的医疗保健实践相比，可提供更好的患者护理。

Project Summary The Substance Abuse and Mental Health Services Administration (SAMHSA) has set guidelines for illicit drug monitoring for both screening and confirmatory tests. Point-of-care (POC) screening assays usually rely upon immunoassays that lack specificity among compounds in a given drug class. Confirmation testing usually employs chromatography coupled to mass spectrometry (MS), which is a powerful technique capable of identifying the relevant analytes of interest in complex samples; however, this approach requires large, expensive equipment that requires technical expertise to operate, thus precluding it from POC environments. In this Fast-Track SBIR project, scientists at Axcend Corporation in collaboration with chromatography and drug analysis experts in academia and advice from practicing health care professionals will pursue further development of a compact capillary liquid chromatography (LC) platform for rapid POC screening of drugs of abuse. In Phase I, sample preparation with a novel solid phase extraction (SPE) apparatus will be optimized and automated, a longer pathlength UV absorption detector flow cell will be created, and capillary LC stationary phases and mobile phases will be investigated and selected to achieve SAMHSA testing concentration cutoff limits for relevant compounds using the compact LC system. In Phase II, novel column-column and column- detector combinations, diode-array detection modules, and data processing approaches combining chromatographic retention times and UV absorption ratios will be developed to enhance the analysis of these compounds and provide timely information to support urgent patient treatment decisions. Key aspects of this proposal that are unique to advancing the field of POC chemical analysis using capillary LC are (1) improved sensitivity using novel simple off-line and on-line extraction and concentration devices, and a longer pathlength UV-absorption flow cell; (2) combinations of columns, solvents, and modes of operation for maximum LC separation, and (3) enhanced selectivity of detection using innovative tandem column–UV-detector combinations, (4) a new compact DAD UV-absorption detector for capillary LC, and (5) unique data handling software algorithms for peak deconvolution. These innovations are new to the area of POC analysis as well as to the broad field of capillary LC in general. The results from this project will be a critical step towards the release of a POC drug screening solution that provides improved patient care compared to current healthcare practices.